Germany Analgesics Market Insights Forecasts to 2033

• The Germany Analgesics Market Size was valued at USD 1.86 Billion in 2023
• The Market Size is Growing at a CAGR of 5.07% from 2023 to 2033
• The Germany Analgesics Market Size is Expected to Reach USD 3.05 Billion by 2033

The Germany Analgesics Market Size is Anticipated to Reach USD 3.05 Billion by 2033, growing at a CAGR of 5.07% from 2023 to 2033

Market Overview

Analgesics are medications that relieve pain without affecting consciousness or sensory awareness. They are also known as painkillers or pain relievers. Approximately 12% of adults in Germany use only over-the-counter analgesics, while 8% use only prescription analgesics. Analgesic use has increased over the past decade, particularly among people aged 30–44. Older people tend to use more prescribed analgesics, while younger people tend to use more over-the-counter analgesics. People with low socioeconomic status and those aged 65 or older tend to use more diclofenac. Furthermore, one of the major drivers of the Germany analgesics market is the rising prevalence of chronic pain conditions. Chronic pain affects a significant portion of the German population, leading to a growing demand for efficient pain management solutions.

Report Coverage

This research report categorizes the market for the Germany analgesics based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Germany analgesics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Germany analgesics market.

Driving Factors

Conditions such as arthritis, cancer, neuropathic pain, and musculoskeletal disorders contribute to the rising load of chronic pain. As a result, there is a need for analgesic drugs that offer relief and improve the quality of life for patients. The growing awareness about pain management, together with advancements in pharmaceutical research, drives the development of new and improved analgesic medications, further propelling the market growth.

Restraining Factors

One of the key restraints of the Germany analgesics market is the potential for side effects and abuse associated with certain analgesic drugs. Opioid-based analgesics, in particular, carry a risk of dependence, addiction, and overdose. The abuse of these drugs has become an important public health concern, leading to regulatory scrutiny and the implementation of stricter prescription guidelines.

Market Segmentation

The Germany analgesics market share is classified into drug type and route of administration.

• The non-opioid segment is expected to hold the largest market share through the forecast period.

The Germany analgesics market is segmented by drug type into opioid, non-opioid, and compound medication. Among these, the non-opioid segment is expected to hold the largest market share through the forecast period. The rising need for non-opioid pain relievers is a result of their lower risk of side effects, wide availability in generic forms, and efforts by private organizations and governments to promote their use in pain management. The growth is also supported by the positive outcomes of non-opioid medications in clinical studies.

• The oral segment is expected to dominate the Germany analgesics market during the forecast period.       

Based on the route of administration, the Germany analgesics market is divided into oral, parenteral, transdermal, and others. Among these, the oral segment is expected to dominate the Germany analgesics market during the forecast period. The segment growth is boosted by factors like the easy administration of pain relief medication through the oral route and its non-invasive nature. The market for the oral segment experienced growth due to pharmaceutical companies' increased research and development endeavors to create new oral pain relievers with reduced side effects and a lower risk of drug overdose.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Germany analgesics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Mallinckrodt Pharmaceuticals
• Anqiu Luan Pharmaceutical
• Novacyl
• BASF
• Anhui BBCA Pharmaceuticals
• Hubei Biocause
• Xinhua Pharm
• Huagang Pharm
• Hebei Jiheng Pharmaceutical
• Zhejiang Kangle Pharmaceutical
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2024, Grünenthal announced the acquisition of US-based Valinor Pharma, LLC (“Valinor”) and its product Movantik (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. Grünenthal would finance the transaction using available liquidity.

Market Segment

This study forecasts revenue at Germany, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Germany Analgesics Market based on the below-mentioned segments

Germany Analgesics Market, By Drug Type

• Opioid
• Non-Opioid
• Compound Medication

Germany Analgesics Market, By Route of Administration

• Oral
• Parenteral
• Transdermal
• Others